Short‐term evolution of HIV‐1 viraemia and CD4+ cell counts in patients who have a primary mutation to zidovudine
Short‐term evolution of HIV‐1 viraemia and CD4+ cell counts in patients who have a primary mutation to zidovudine
复制标题
具有齐多夫定原发突变的患者中 HIV-1 病毒血症和 CD4+ 细胞计数的短期演变
DOI：
--
复制
发表时间：
1998
期刊：
影响因子：
--
通讯作者：
E. Lissen
中科院分区：
文献类型：
--
作者：
A. Rubio;M. Leal;C. Rey;J. Pineda;A. Sánchez;E. Lissen
目的：研究抗逆转录病毒治疗（包括齐多夫定）的不同反应，对齐多夫定、血清病毒载量和CD 4+细胞计数具有原发耐药的HIV患者，在治疗开始时，在一组HIV pol基因密码子215突变的抗逆转录病毒初治患者和对照组中持续24周。设计：病例对照回顾性研究（1989-1996）。方法：在先前研究的210例患者中，有19例携带密码子215突变，自我报告治疗依从性，最短随访时间为24周，并单独使用齐多夫定或与其他核苷类似物联合治疗。通过初始CD 4+细胞计数、临床状态和抗逆转录病毒治疗，将这些患者与19例入组时携带野生型菌株的患者相匹配。结果：在前12周，CD 4+细胞计数增加（野生型和突变病毒感染组分别为76 ± 26和64 ± 26 × 106/l），直到第24周略有下降，尽管研究的两组之间没有发现显著差异。两组的血清病毒载量均降低（野生型和突变型病毒感染的血清病毒载量变化分别为0.80 ± 0.11 log 10和0.87 ± 0.26 log 10拷贝/ml），但组间无显著差异。结论：在通过血清病毒载量和CD 4+细胞计数测量的短期应答方面，齐多夫定原发突变患者和携带野生型病毒的对照患者之间没有发现显著差异。
Objective:To investigate the different responses to antiretroviral treatment including zidovudine, of patients harbouring HIV with primary resistance to zidovudine, serum viral load, and CD4+ cell counts, for 24 weeks in a group of antiretroviral-naive patients with the codon 215 mutation of the HIV pol gene and in a control group at the start of treatment. Design:A case–control retrospective study (1989–1996). Method:Nineteen out of 210 patients previously studied harboured the codon 215 mutation, had a self-reported compliance with treatment, a minimum follow-up of 24 weeks, and were treated with zidovudine alone or in combination with other nucleoside analogues. These patients were matched with 19 patients with wild-type strains at entry by initial CD4+ cell counts, clinical status, and antiretroviral treatment. Results:During the first 12 weeks, CD4+ cell counts increased (76 ± 26 and 64 ± 26 × 106/l in wild-type and mutant virus-infected groups, respectively), decreasing slightly until week 24, although no significant differences were found between the two groups studied. Serum viral load decreased in both groups (change in serum viral load of 0.80 ± 0.11 log10 and 0.87 ± 0.26 log10 copies/ml, wild-type and mutant virus-infected, respectively), although no significant differences were found between groups. Conclusion:No significant differences were found between patients with the primary mutation to zidovudine and control patients harbouring wild-type virus in terms of short-term response measured by serum viral load and CD4+ cell counts.